Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter 2026, ...
Leasing and occupancy ahead of expectations • Disposition program is on track • Net debt to EBITDA continues to improve TORONTO, July ...
Welcome to Horizon, DLA Piper’s monthly bulletin reporting on late-breaking legislative and policy developments in sustainability. Our aim is to ...
Tempus is increasing its full year 2026 revenue guidance to $1.595 to $1.605 billion, which represents ~25% annual growth. We continue to expect 2026 Adjusted EBITDA to be ~$65 million. Guidance ...
Read Q&As from DFL candidates Louis McNutt and Dan Fiskum on data center development, political division, affordability, ...
The Eastman team delivered a strong second quarter despite continued dynamic macroeconomic conditions,” said Mark Costa, Board Chair and CEO. “Sales revenue increased 15 percent sequentially driven by ...
Leasing and occupancy ahead of expectations • Disposition program is on track • Net debt to EBITDA continues to improve TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Allied Properties Real Estate ...
The Demerger is conditional upon approval by the Extraordinary General Meeting (the "EGM") of the Company, which is expected to be held on 7 December 2026, and upon the Share Exchange Agreement (as ...
Spread the loveHold onto your digital wallets, folks, because the future of cybersecurity looks a lot more expensive and a ...
FRAMINGHAM, Mass.-- (BUSINESS WIRE)--Aug 3, 2026-- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results